{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-24-024213","form_type":"8-K/A","ticker":null,"cik":"0000859737","company_name":"HOLOGIC INC","filed_at":"2024-05-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:22.158613+00:00","generated_at":"2026-06-02T23:36:52.690386+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Hologic Q2 beats: revenue $1,018M, adj EPS $1.03; raises FY24 guidance; acquires Endomagnetics for $310M","bullets":["Q2 revenue $1,017.8M (down 0.8% YoY) exceeded guidance; GAAP diluted EPS $0.72, non-GAAP $1.03.","Organic revenue ex-COVID grew 4.9% constant currency; Diagnostics ex-COVID +9.8%, Surgical +7.4%.","Company raised full-year revenue midpoint in constant currency and EPS guidance on strong margins.","Agreed to acquire Endomagnetics Ltd for ~$310M, adding breast cancer surgery technologies.","Cash flow from operations $292.4M; cash generation remains strong."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-24-024213","json":"https://secwatch.observer/filing/0001140361-24-024213.json","markdown":"https://secwatch.observer/filing/0001140361-24-024213.md","text":"https://secwatch.observer/filing/0001140361-24-024213.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/859737/000114036124024213/0001140361-24-024213-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/859737/000114036124024213/ef20028431_8ka.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T23:36:52.690386+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b58ca9eb5bacfd630940ea9cc10114b238be1bf3","claim":"HOLOGIC INC reported the second quarter ended March 30, 2024 results: revenue $1,017.8 million, EPS $0.72. Guidance raised.","evidence_excerpt":"Hologic Announces Financial Results for Second Quarter of Fiscal 2024 – Revenue of $1,017.8 Million, GAAP Diluted EPS of $0.72, and Non-GAAP Diluted EPS of $1.03; Revenue and Non-GAAP Diluted EPS Exceeded Guidance – – Total Company Organic Revenue Growth Excluding COVID-19 of 4.9% in Constant Currency; Against a 21.9% Prior Year Period Comparable – – Company Raises Full-Year Revenue Midpoint in Constant Currency and Raises EPS Guidance on Strong Margins","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/859737/000114036124024213/0001140361-24-024213-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the second quarter ended March 30, 2024"},{"label":"Revenue","value":"$1,017.8 million"},{"label":"EPS","value":"$0.72"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}